Analysts Set Novo Nordisk A/S (NYSE:NVO) Target Price at $53.93

Shares of Novo Nordisk A/S (NYSE:NVO) have been assigned a consensus recommendation of “Hold” from the twenty-three research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $49.9286.

A number of research firms recently commented on NVO. TD Cowen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective for the company. in a research note on Tuesday. Kepler Capital Markets lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. CICC Research started coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target on the stock. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $38.82 on Monday. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 1 year low of $35.85 and a 1 year high of $82.57. The company has a market cap of $173.31 billion, a PE ratio of 11.19 and a beta of 0.73. The stock’s 50-day moving average price is $50.69 and its two-hundred day moving average price is $52.02.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is 52.74%.

Institutional Trading of Novo Nordisk A/S

A number of hedge funds have recently made changes to their positions in NVO. True Wealth Design LLC increased its stake in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after buying an additional 300 shares during the period. Guerra Advisors Inc acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $25,000. Godfrey Financial Associates Inc. purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $25,000. WealthCollab LLC grew its holdings in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares in the last quarter. Finally, American National Bank & Trust acquired a new position in shares of Novo Nordisk A/S in the fourth quarter worth $28,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Deal with Hims & Hers resolves a legal feud and opens the telehealth channel to sell FDA‑approved Ozempic and Wegovy, which could shift patients away from compounded alternatives and support volume recovery. Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
• Neutral Sentiment: India’s regulator warned against direct or surrogate advertising for weight‑loss drugs, which could constrain marketing strategies in a fast‑growing market but is not an immediate sales sanction. India warns drugmakers against direct or surrogate weight-loss drug and obesity ads
• Negative Sentiment: FDA issued a warning letter over failures in post‑marketing adverse event reporting tied to semaglutide (Ozempic/Wegovy), citing potential unreported serious events including deaths and a suicide — this raises regulatory risk and a near‑term compliance/oversight overhang. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: Sell‑side and street pressure: TD Cowen downgraded NVO and other analysts flag that the pipeline may not blunt semaglutide loss‑of‑exclusivity (LOE) headwinds — reinforcing negative sentiment after guidance cuts. Novo Nordisk downgraded as pipeline ‘not poised to blunt semaglutide LOE’
• Negative Sentiment: Investor legal pressure: law firm Pomerantz announced an investigation into Novo Nordisk investors, signaling possible litigation risk and additional headline volatility. Pomerantz law firm investigates claims on behalf of investors of Novo Nordisk
• Negative Sentiment: Competitive pressure: Eli Lilly’s aggressive investments and programs (including China expansion and employer/coverage initiatives) keep the GLP‑1 market intensely competitive, which could pressure Novo’s pricing and market share over time. The Real Reason Eli Lilly Is Pouring $3 Billion Into China

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.